Skip to content

Mirum Pharmaceuticals, Inc. MIRM Shares Reserved for Future Issuance Under Stock Plans

Shares Reserved for Future Issuance Under Stock Plans at other companies

Merck & Co. logo
Merck & Co.MRK
66M-12.0%
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s shares reserved for future issuance under stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s shares reserved for future issuance under stock plans?
Mirum Pharmaceuticals, Inc. (MIRM) reported shares reserved for future issuance under stock plans of 29.2M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s shares reserved for future issuance under stock plans changed year-over-year?
Mirum Pharmaceuticals, Inc.'s shares reserved for future issuance under stock plans increased by 7.7% year-over-year, from 27.1M to 29.2M.
What does shares reserved for future issuance under stock plans mean?
This represents the total number of common shares authorized and set aside for future issuance to employees and directors under equity compensation plans. It provides insight into the potential future dilution of existing shareholders. Investors monitor this to assess the firm's long-term incentive structure.